These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35841036)

  • 1. Improving equity and access to buprenorphine treatment through telemedicine at syringe services programs.
    Lambdin BH; Kan D; Kral AH
    Subst Abuse Treat Prev Policy; 2022 Jul; 17(1):51. PubMed ID: 35841036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation.
    Corneli A; Perry B; Des Marais A; Choi Y; Chen H; Lilly R; Ayers D; Bennett J; Kestner L; Meade CS; Sachdeva N; McKellar MS
    Harm Reduct J; 2022 Dec; 19(1):132. PubMed ID: 36463214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-Threshold Buprenorphine via Community Partnerships and Telemedicine-Case Reports of Expanding Access to Addiction Treatment During COVID-19.
    Levander XA; Wheelock H; Pope J; Lee A; Hartmann K; Abuelkhair S; Gregg JL; Buchheit BM
    J Addict Med; 2022 Jan-Feb 01; 16(1):e56-e58. PubMed ID: 34374502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low Barrier Tele-Buprenorphine in the Time of COVID-19: A Case Report.
    Harris M; Johnson S; Mackin S; Saitz R; Walley AY; Taylor JL
    J Addict Med; 2020; 14(4):e136-e138. PubMed ID: 32433364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs.
    Adams JW; Savinkina A; Fox A; Behrends CN; Madushani RWMA; Wang J; Chatterjee A; Walley AY; Barocas JA; Linas BP
    Addiction; 2022 Oct; 117(10):2635-2648. PubMed ID: 35315148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System's Initiative to Expand Treatment Access During the COVID-19 Pandemic.
    Tofighi B; McNeely J; Walzer D; Fansiwala K; Demner A; Chaudhury CS; Subudhi I; Schatz D; Reed T; Krawczyk N
    J Addict Med; 2022 Jan-Feb 01; 16(1):e40-e43. PubMed ID: 33560696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Red Flags' and 'Red Tape': Telehealth and pharmacy-level barriers to buprenorphine in the United States.
    Textor L; Ventricelli D; Aronowitz SV
    Int J Drug Policy; 2022 Jul; 105():103703. PubMed ID: 35561484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
    Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation.
    Jakubowski A; Rath C; Harocopos A; Wright M; Welch A; Kattan J; Navos Behrends C; Lopez-Castro T; Fox AD
    Harm Reduct J; 2022 Jul; 19(1):75. PubMed ID: 35818071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of a medical student-run telemedicine program for medications for opioid use disorder during the COVID-19 pandemic.
    Castillo M; Conte B; Hinkes S; Mathew M; Na CJ; Norindr A; Serota DP; Forrest DW; Deshpande AR; Bartholomew TS; Tookes HE
    Harm Reduct J; 2020 Nov; 17(1):88. PubMed ID: 33203460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic.
    Wang L; Weiss J; Ryan EB; Waldman J; Rubin S; Griffin JL
    J Subst Abuse Treat; 2021 May; 124():108272. PubMed ID: 33771276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes.
    Hammerslag LR; Talbert J; Slavova S; Lei F; Freeman PR; Marks KR; Fanucchi LC; Walsh SL; Lofwall MR
    J Subst Use Addict Treat; 2024 Sep; 164():209391. PubMed ID: 38740189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
    Nunes EV; Levin FR; Reilly MP; El-Bassel N
    J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low Threshold Telemedicine-based Opioid Treatment for Criminal Justice Involved Adults During the COVID-19 Pandemic: A Case Report.
    Flavin L; Tofighi B; Krawczyk N; Schatz D; McNeely J; Butner J
    J Addict Med; 2022 Jan-Feb 01; 16(1):e59-e61. PubMed ID: 35120069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "We'll be able to take care of ourselves" - A qualitative study of client attitudes toward implementing buprenorphine treatment at syringe services programs.
    Frost T; Deutsch S; Brown S; Lemien E; Cunningham CO; Fox AD
    Subst Abus; 2021; 42(4):983-989. PubMed ID: 33759722
    [No Abstract]   [Full Text] [Related]  

  • 17. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives.
    Aronowitz SV; Engel-Rebitzer E; Dolan A; Oyekanmi K; Mandell D; Meisel Z; South E; Lowenstein M
    Harm Reduct J; 2021 Nov; 18(1):119. PubMed ID: 34823538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
    Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
    JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic.
    Mattocks KM; Moore DT; Wischik DL; Lazar CM; Rosen MI
    J Subst Abuse Treat; 2022 Aug; 139():108777. PubMed ID: 35346533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.